Accordingly, the PD-1-inhibited NK cells, with direct activation and potent cytotoxicity, lack of MHC-restriction, and most importantly, no PD-1-mediated immunosuppression, could be a more feasible immune therapeutic approach against GBM. Here, PDCD1 is linked to glioblastoma.